Company intelligence / Profile preview

Zion Pharma

Shanghai, Shanghai, Chinazionpharma.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Zion Pharma develops small-molecule drugs for oncology, focusing on brain-permeable compounds. Its lead asset, ZN-A‑1041—a blood-brain barrier penetrant oral HER2 tyrosine kinase inhibitor—was licensed globally to Roche in a deal worth up to $680M. The drug aims to treat or prevent brain metastases in patients with HER2-positive metastatic breast cancer and had reached Phase 1 trials before the partnership. Additional programs include an ATM inhibitor for advanced solid tumors.[1][2][3]

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

ZN-A-1041

Phase 1

Indications: HER2-positive metastatic breast cancer, Brain metastases

Partnerships

Roche – global rights agreement for ZN-A‑1041 ($70M upfront, up to $610M milestones plus royalties); Roche leads further development and commercialization.[6]

Beyond the preview

Go deeper on Zion Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zion Pharma.

Explore the full profile